Brian Ghoshhajra, MD, MBA, division chief, cardiovascular imaging, Massachusetts General Hospital and associate professor of radiology, Harvard Medical School, explains the impact of the iodine contrast shortage on computed tomography (CT) and cardiac imaging.
 

Production at the facility in Shanghai is expected to be near 100% starting on June 6.

Prior imaging of the descending thoracic and abdominal aorta in study participants revealed thoracic aortic wall area (AWA), plaque prevalence and plaque volumes to be independently associated with incident CVD.

In a blind pilot study, inexperienced users successfully captured images for 100% of patients using AI guidance.

The American College of Radiology (ACR) announced this week its government relations staff has been engaging federal agencies in an effort to improve product availability and hasten resolution of the ongoing iodine contrast shortage.

Alan Matsumoto, MD, chair of the department of radiology at the University of Virginia and vice chair of the ACR Board of Chancellors, explains how the ACR and group purchasing organizations are asking the FDA to mitigate the contrast shortage with an emergency use authorization to allow non-FDA cleared iodine contrast agents to be imported.

Randall Thompson, MD, immediate past president of the American Society of Nuclear Cardiology, said the group had issues with the document's elevation of cardiac CT and FFR-CT. 

The new technique is still in the development stage, but early research suggests it could provide clinicians with a new treatment option for breaking down arterial plaque.